ASA1-OT5

ASA1-OT5 is an experimental **peptide-drug conjugate** described in preclinical glioblastoma research. It consists of a salicylanilide-derived small molecule payload linked through an oxime bond to an oligotuftsin carrier peptide designed to enhance tumor-cell uptake, with the carrier selected for interaction with neuropilin receptor-associated glioblastoma targeting pathways. In vitro, ASA1-OT5 was evaluated in U87 human glioblastoma cells, where salicylanilide conjugates in this series reduced cell viability and were associated with autophagy-related cell death signaling. The agent appears to be a research compound rather than a clinically developed drug, and its precise molecular target and developer/manufacturer are not clearly established from the provided evidence.